Geriatric-CO-mAnagement for Cardiology Patients in the Hospital (G-COACH)

February 11, 2020 updated by: Universitaire Ziekenhuizen KU Leuven

Quasi-experimental Before-and-after Study to Compare the Effectiveness of Geriatric Co-management on Preventing Functional Decline as Compared to Standard of Care in Older Cardiology Patients

The primary objective of the evaluation study is to determine if geriatric co-management is superior to standard of care in preventing functional decline in older patients admitted for acute heart disease or Transcatheter Aortic Valve Implementation (TAVI) to the cardiology units of the University Hospitals Leuven.

Study Overview

Detailed Description

This study aims to implement and evaluate a geriatric co-management intervention in older patients admitted for acute heart disease or Transcatheter Aortic Valve Implementation (TAVI) to the cardiology units of the University Hospitals Leuven. The study uses a mixed-methods methodology aiming to 1) assess the feasibility and evaluate the effectiveness of geriatric co-management, 2) describe the experiences of intervention participants, and 3) perform a process evaluation. We will first consecutively recruit patients on the cardiology units to measure the standard of care in the control group. The geriatric co-management intervention will then be implemented and piloted on the participating units. Once fully implemented, we will consecutively recruit patients for the intervention group who will receive the geriatric co-management intervention.

Study Type

Interventional

Enrollment (Actual)

454

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgium, 3000
        • University Hospitals Leuven

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

75 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria: Patients will be included if they:

  • Are admitted for non-surgical treatment of an acute heart problem (patients may be admitted through the emergency department or the cardiology outpatient services for any heart related acute disease) OR if they are admitted for Transcatheter Aortic Valve Implantation (TAVI);
  • Are aged 75 years or older;
  • Have an expected length of stay of three days or longer;
  • Non-palliative on hospital admission
  • Are Dutch speaking and testable;
  • Give informed consent or proxy-informed consent;

Exclusion Criteria: Patients will be excluded if they:

  • Are admitted from another hospital unit or other hospital;
  • Have been admitted to the intensive care unit for three days or longer;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cardio-geriatric co-management
A geriatric co-management intervention will be implemented on the cardiology units of the University Hospitals Leuven. Geriatric co-management is defined as a shared responsibility and decision making between the cardiology team and the geriatric team who provides complementary medical care in the prevention and management of geriatric problems. Patients included in the co-management program will undergo a comprehensive geriatric assessment within 24 hours of hospital admission.

A comprehensive geriatric assessment on admission will stratify patients in groups:

  1. Low risk patients are expected to do well and will not receive co-management.
  2. Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.
  3. High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.
No Intervention: Standard of care
The control group will receive the standard of care on the cardiology units. This includes multidisciplinary care with a one weekly multidisciplinary team meeting. Team members include a cardiology resident (supervised by a cardiologist), ward nurses, a physical therapist, a social worker and a dietician. A geriatric consultation team is available for consultation services if requested by the cardiology team.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional status on activities of daily living assessed using the Katz Index of Activities of Daily Living.
Time Frame: Hospital admission (baseline) up to hospital discharge around an average of 12 days.
A difference of 1 point on the Katz Index will be considered clinically relevant.
Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Functional decline in activities of daily living assessed using the Katz Index of Activities of Daily Living
Time Frame: Hospital admission (baseline) up to hospital discharge around an average of 12 days.
A decline of 1 point between admission and discharge on the Katz Index will be considered clinically relevant.
Hospital admission (baseline) up to hospital discharge around an average of 12 days.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional decline in activities of daily living assessed using the Barthel Index of Activities of daily. Living.
Time Frame: Hospital admission (baseline), hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Hospital admission (baseline), hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Community mobility assessed using the Life-Space assessment.
Time Frame: Hospital admission (baseline), and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Hospital admission (baseline), and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Short Physical Performance Test (SPPB).
Time Frame: Hospital admission (baseline), up to at hospital discharge around an average of 12 days.
The SPPB consist of gait speed, balance test, and chair stand test.
Hospital admission (baseline), up to at hospital discharge around an average of 12 days.
Peak handgrip force assessed at the dominant side with the elbow at 90° of flexion, and the forearm and wrist in a neutral position.
Time Frame: Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Isometric handgrip force will be measured with a hydraulic hand dynamometer (Jamar dynamometer; JA Preston Corporation; Jackson, MI).
Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Symptomatic infections defined by a clinical diagnosis of pneumonia, urinary tract infection, sepsis and wound infection.
Time Frame: Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Delirium assessed using the 3D confusion assessment method.
Time Frame: Hospital admission (baseline) and on day 3, 5, 7 and 9 (or every day when a patient is delirious).
Hospital admission (baseline) and on day 3, 5, 7 and 9 (or every day when a patient is delirious).
Cognitive status assessed using the Mini-Cog.
Time Frame: Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Falls and fall related injuries.
Time Frame: Hospital admission (baseline), hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
A fall incident is defined as an unexpected event in which the patient comes to rest on the ground, floor or lower level. Fall related injuries will be divided in two groups: minor and major.
Hospital admission (baseline), hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Obstipation assessed using nurses recorded observations.
Time Frame: Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Obstipation is defined as not having passed stool in five days or more.
Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Length of hospital stay.
Time Frame: Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Hospital admission (baseline) up to hospital discharge around an average of 12 days.
Institutionalization.
Time Frame: hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
New admission to nursing home or skilled nursing facility
hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Thirty day unplanned readmission rate.
Time Frame: 30 days follow-up after hospital discharge.
30 days follow-up after hospital discharge.
Survival
Time Frame: Hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Time to death
Hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Quality of life assessed using the EQ-5D.
Time Frame: Hospital admission (baseline), hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Hospital admission (baseline), hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Quality of life index assessed by converting the EQ-5D using standardized index values.
Time Frame: Hospital admission (baseline), hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Hospital admission (baseline), hospital discharge around an average of 12 days, and at 30 days, 3 months and 6 months follow-up after hospital discharge.
Functional status on activities of daily living assessed using the Katz Index of Activities of Daily Living.
Time Frame: At 30 days, 3 months and 6 months follow-up after hospital discharge.
Functional status will be measured using the Katz Index of Activities of Daily Living.
At 30 days, 3 months and 6 months follow-up after hospital discharge.
Unplanned hospital readmissions
Time Frame: up to 6 months follow-up after hospital discharge
Time to the first unplanned hospital readmission
up to 6 months follow-up after hospital discharge
Hospital costs
Time Frame: Between hospital admission and discharge, an average of 12 days
Costs registered for to the treatment, care, logistics and stay in the hospital
Between hospital admission and discharge, an average of 12 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Experiences by the intervention participants using focus group discussions and individual interviews.
Time Frame: Through study completion, an average of 1 year.
The interviews will focus on implementation determinants and the interaction of the intervention with the context in which it was implemented.
Through study completion, an average of 1 year.
Reach of the intervention using structured observations and process indicators.
Time Frame: Through study completion, an average of 1 year.
Reach is defined as the number of eligible patients receiving the intervention.
Through study completion, an average of 1 year.
Fidelity of the intervention using structured observations and process indicators.
Time Frame: Through study completion, an average of 1 year.
Fidelity is defined as the extent to which the intervention was implemented as defined in the protocol.
Through study completion, an average of 1 year.
Dose of the intervention using structured observations and process indicators.
Time Frame: Through study completion, an average of 1 year.
Dose is defined as the number of intervention components delivered as defined in the protocol.
Through study completion, an average of 1 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Johan Flamaing, PhD, MD, Universitaire Ziekenhuizen KU Leuven
  • Principal Investigator: Koen Milisen, PhD, MSN, University of Leuven
  • Principal Investigator: Mieke Deschodt, PhD, MSN, University of Leuven

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2016

Primary Completion (Actual)

December 1, 2018

Study Completion (Actual)

July 1, 2019

Study Registration Dates

First Submitted

August 24, 2016

First Submitted That Met QC Criteria

August 31, 2016

First Posted (Estimate)

September 7, 2016

Study Record Updates

Last Update Posted (Actual)

February 13, 2020

Last Update Submitted That Met QC Criteria

February 11, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 22/15/028

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on Cardio-geriatric co-management

3
Subscribe